STRATIFICATION ACCORDING TO HGG-IMMUNO RPA MODEL PREDICTS OUTCOME IN PATIENTS WITH RELAPSED MALIGNANT GLIOMA TREATED BY ADJUVANT POSTOPERATIVE DC VACCINATION KU LeuvenSteven De Vleeschouwer, Hilko Ardon, Frank Van Calenbergh, Raf Sciot, Guy Wilms, Johan van Loon, Jan Goffin, Stefaan Van Gool
Management of Cervical Spine Chordomas. Case Report KU LeuvenBart Depreitere, Vincent Vander Poorten, Jan Vranckx, Joannes Menten
Integration of DC vaccination in the primary treatment of adults with glioblastoma: final results of the HGG-2006 phase I/II trial KU LeuvenHilko Ardon, Stefaan Van Gool, W Maes, Steven De Vleeschouwer, et al.
Myeloid-derived suppressor cells: another hurdle for glioblastoma immunotherapy KU LeuvenWim Maes, Hilko Ardon, Marc Van Haaren, Steven De Vleeschouwer, et al.
INTRINSIC GENE EXPRESSION PROFILES OF GLIOMAS ARE A BETTER PREDICTOR OF SURVIVAL THAN HISTOLOGY KU LeuvenLonneke Gravendeel, Mathilde Kouwenhoven, Olivier Gevaert, Johan de Rooi, Andrew Stubbs, J Duijm, Anneleen Daemen, Fonnet Bleeker, Linda BC Bralten, Nanne Kloosterhof, et al.
Validation of RPA classification as a prognostic tool in adult patients with relapsed high-grade glioma vaccinated at time of recurrence KU LeuvenSteven De Vleeschouwer, Hilko Ardon, Frank Van Calenbergh
Abstracts from the 2009 Joint Meeting of the Society for Neuro-Oncology (SNO) and the American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Section on Tumors: October 22–24, 2009: New Orleans, LA KU LeuvenSteven De Vleeschouwer
Integration of DC vaccination in the primary treatment of adults with GBM: update of the HGG-2006 phase I/II trial KU LeuvenHilko Ardon, Stefaan Van Gool, Wim Maes, Steven De Vleeschouwer, et al.
Abstracts for the Thirteenth Annual Meeting of the Society for Neuro-Oncology: November 20–23, 2008 KU LeuvenSteven De Vleeschouwer